Resistance to BRAF and MEK inhibitors in BRAFV600E melanoma has been linked to compensatory activation of cAMP-dependent signaling networks, involving PKA, and CREB (Johannessen et al., 2013). This evidence concerns the gene MAP2K7 and melanoma.